Acura Pharmaceuticals, Inc. · OTC:ACUR
Acura Pharmaceuticals — Rodman & Renshaw Conference 2017
24 slides from Acura Pharmaceuticals's conference presentation, Sep 11, 2017

Slide 1: Rodman & Renshaw Conference, September 2017
CONFIDENTIAL Symbol: ACUR September 2017 Rodman & Renshaw Conference © 2017 Acura Pharmaceuticals, Inc. All Rights Reserved

Slide 2: General Caution Regarding Forward Looking Statements
Symbol: ACUR General Caution Regarding Forward Looking Statements Certain statements in this presentation constitute “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 . Such forwarding - looking statements involve known and unknown risks, uncer

Slide 3: Acura's Abuse Deterrent Technology Platforms
Symbol: ACUR Acura’s Abuse Deterrent Technology Platforms Opioid Abuse – Oral Excessive Tablet Abuse Exploratory Stage Development Un - partnered Issued US Patents to 2033 Pseudoephedrine – Conversion to Meth Two US Marketed Nexafed® Products License to MainPointe Pharma Issued US Pa

Slide 4: A Need for Oral Excessive Tablet Abuse Technologies
Symbol: ACUR • April 2015 FDA Guidance “Abuse Deterrent Opioid – Evaluation and Labeling” • Immediate - release opioids containing acetaminophen (APAP) • Predominately abused by the oral route • Addressing nasal abuse may not meaningfully reduce abuse • July 2017 Prime Therapeutics Press Release • “

Slide 5: LIMITx Benefits (Unsolicited)
Symbol: ACUR LIMITx ™ Benefits (Unsolicited) As identified by o pioid prescribers 5 Source: Company Physician Focus Groups; n=8

Slide 6: The LIMITx Technology
Symbol: ACUR Illustration The LIMITx ™ Technology Product Formulation • Micro - particles containing the opioid active ingredient • Functional tablet matrix of other ingredients Oral Abuse Deterrence • Tablet matrix acts synergistically with the micro - particle ingredients to retard the release of

Slide 7: LIMITx Technology Objectives
Symbol: ACUR OBJECTIVES #1 To provide meaningful analgesic blood levels of drug at the recommended single tablet dose #2 To reduce the peak drug levels in the blood when more than the recommended dose is ingested LIMITx ™ Technology Objectives 7 CHALLENGES #1 : Find the appropriate buffer level that

Slide 8: LIMITx Studies To Date
Symbol: ACUR • LTX - 04 – Immediate - Release Hydromorphone HCl Tablets • Fasted Pharmacokinetic Studies AP - LTX - 400 and AP - LTX - 401 • Studied 1 tablet up to 8 and 7 tablets, respectively LIMITx ™ Studies To Date 8 Formulation Tested Clinical Study Micro - particle Release Buffer Strength LTX

Slide 9: In Vitro Dissolution in pH2 HCl
Symbol: ACUR 9 Study 401 Micro - particles are much faster at pH 2 0 20 40 60 80 100 0 5 10 15 20 % HM in Solution Time (minutes) Dilaudid MP17-slower MP25-faster MP17 used in Study 400 MP25 used in Study 401 Mean fasted gastric pH is 1.3 to 2.1 In Vitro Dissolution in pH2 HCl

Slide 10: One Tablet LTX-04 Dose Cmax is Consistent
Symbol: ACUR 10 One Tablet LTX - 04 Dose Cmax is Consistent 0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 Plasma Conc. Ng/mL DILAUDID LTX-04S LTX-04P Study 400 (n=8) even when the buffer strength and micro - particle release vary 0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 Plasma Conc. Ng/mL HYMP LTX-04P3 Stu

Slide 11: In Vitro Dissolution in pH7 Water
Symbol: ACUR 11 Study 401 Micro - particles Limit Release at pH 7 0 20 40 60 80 100 0 30 60 90 120 % HM in Solution Time (minutes) Dilaudid MP17-slower MP25-faster MP17 used in Study 400 MP25 used in Study 401 Mean fasted gastric pH is 1.3 to 2.1 In Vitro Dissolution in pH7 Water

Slide 12: Multi-Tablet LTX-04 Dose Cmax is Further Reduced
Symbol: ACUR 12 Multi - Tablet LTX - 04 Dose Cmax is further reduced 0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 Plasma Conc. Ng/mL HYMP LTX-04P3 0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 Plasma Conc. Ng/mL DILAUDID LTX-04P Study 400 (n=8) Study 401 (n=13) 7 Tabs Normalized 8 Tabs Normalized as more buffe

Slide 13: Increasing Tablets: Buffer Impact on Cmax / Tmax
Symbol: ACUR -80% -60% -40% -20% 0% Increasing Tablets [Buffer] Impact on Cmax / Tmax 13 -40% -20% 0% 20% 40% Study 400 % Change LTX - 04P versus DILAUDID Cmax by No. of Tabs T max by No. of Tabs 1 2 3 4 6 8 1 2 3 4 6 8 Gastric pH readings in Study 400 provided acid neutralization onset and duration

Slide 14: Gastric Emptying Plays a Role in Delaying Drug Release
Symbol: ACUR 14 Gastric Emptying Plays a Role in Delaying Drug Release 0.00 0.25 0.50 0.75 1.00 1.25 1.50 1.75 2.00 2.25 Tmax (hrs) HYMP LTX-04P3 LTX-04P3 w/ GE agent • Study 401 – 7 tablet dose • Agent introduced to increase gastric emptying time (Increase gastric retention time) Tmax is significan

Slide 15: Delayed LTX-04 Tmax Does Not Impact Cmax
Symbol: ACUR 15 0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 Cmax (ng/mL) HYMP LTX-04P3 LTX-04P3 w/ GE Agent • Study 401 – 7 tablet dose • Agent introduced to increase gastric emptying time (Increase gastric retention time) Despite a lengtehened Tmax with the GE Agent, Cmax for LTX - 04 remains consisten

Slide 16: LIMITx Conclusions and Next Steps
Symbol: ACUR • LTX - 04 (Studies 400 and 401 Conclusions) • We believe the micro - particles are working as designed: • The clinical data to date indicates we can manipulate the extent and duration of the gastric environment which controls the release and absorption of the active ingredient • The ra

Slide 17: Immediate Release Opioids Market Opportunity
Symbol: ACUR Immediate Release Opioids Market Opportunity 2016 Addressable Market (millions) Immediate - release Opioid Reference Brand(s) TRx Tablets Dollars Price/ Tab* Hydrocodone/APAP Vicodin, Norco 88.7 5,433 888 .16 Oxycodone/APAP Percocet 35.1 2,224 841 .38 Oxycodone Roxicodone 20.1 1,775 359

Slide 18: Study AP-LTX-03 Design
Symbol: ACUR 18 Study AP - LTX - 300 Design 56 subjects enrolled 8 Subj. 1 Norco® 8 Subj. LTX - 03 + 0 Buffer 8 Subj. LTX - 03 + 1 Buffer 8 Subj. LTX - 03 + 2x Buffer 8 Subj. LTX - 03 + 3x Buffer 8 Subj. LTX - 03 + 4x Buffer 8 Subj. LTX - 03 + 5x Buffer Norco = Hydrocodone Bitartrate/APAP 10/325mg t

Slide 19: Acura's Other Technologies
Symbol: ACUR 19 Acura’s Other Technologies Aversion® Opioid Analgesic • FDA approved ( Oxaydo ®) • Differentiated abuse deterrent label (snorting) • Oxaydo ® Licensed worldwide to Egalet Corp. • Stepped Royalties • Aversion® licensed to Kempharm for their prodrugs • Royalty Impede® Pseudoephedrine N

Slide 20: Acura Pharmaceuticals Summary
Symbol: ACUR Acura Pharmaceuticals Summary 20

Slide 21: Acura Product Pipeline Overview
Symbol: ACUR 21 AVERSION® Immediate - Release Opioids NEXAFED® with IMPEDE® (Pseudoephedrine (PSE)) 30mg Tablets Sinus Pressure + Pain Oxaydo® (oxycodone HCl) 7 Opioid Formulations 12 Hour PSE/ Loratadine LIMITX™ Immediate - Release O pioids LTX - 04 LTX - 03 Formulation & Stability Clinical & Lab T

Slide 22: Intellectual Property Position
Symbol: ACUR • Limitx™ Technology: U.S. issued patents expire 2033 • 3 U.S. patents issued • 9,101,636 - 9,320,796 - 9,662,393 • Patents issued in selected foreign jurisdictions • Aversion® Technology: U.S. issued patents expire 2023 to 2025 • 6 U.S. patents issued • US Generic market entry January

Slide 23: Expectations for 2017
Symbol: ACUR • Limitx™ Technology • Results from Study AP - LTX - 300 expected October 2017 • Determine commercial LTX - 03 formulation • Commence LTX - 03 NDA studies in 2018 • Evaluate LIMITx ™ for additional drug classes • Complete formulation work on PSE/ Loratadine in first half 2018 • Pursue f

Slide 24: Acura Pharmaceuticals, Inc. contact details
CONFIDENTIAL Symbol: ACUR Acura Pharmaceuticals, Inc. 616 N. North Court, Suite 120 Palatine, IL 60067 (847) 705 - 7709 www.AcuraPharm.com
Source: SEC EDGAR · 8-K filed Sep 11, 2017
More decks from Acura Pharmaceuticals, Inc.
Technical Presentation (June 2017)11 slides · Jun 28, 2017
Technical Presentation (July 2016)14 slides · Jul 13, 2016
Technical Presentation (June 2016)12 slides · Jun 8, 2016
Technical Presentation (April 2016)13 slides · Apr 14, 2016
Investor Presentation (March 2016)19 slides · Mar 11, 2016
Investor Presentation (September 2015)23 slides · Sep 28, 2015